Home > Healthcare > Medical Services > Inpatient and Outpatient Services > Colorectal Cancer Therapeutics Market

Colorectal Cancer Therapeutics Market Share

Report ID: GMI9808
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Colorectal Cancer Therapeutics Market Share

The competitive landscape of the colorectal cancer therapeutics industry is marked by intense rivalry among major pharmaceutical companies and biotech firms, each striving to gain a significant foothold in the market. Key players leverage their extensive portfolios and innovative treatment approaches to maintain a competitive edge.

Colorectal Cancer Therapeutics Market Companies

Prominent players operating in the colorectal cancer therapeutics industry include:

Amgen Inc.
Bayer AG
Bristol-Myers Squibb Company
Celleron Therapeutics
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Sumitomo Pharma Co., Ltd.
Regeneron Pharmaceuticals, Inc.
TAIHO PHARMACEUTICAL CO., LTD
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of colorectal cancer therapeutics reached USD 12.4 billion in 2023 and is set to witness 4.6% CAGR through 2032, owing to rising incidence rates, as well as advancements in targeted and cancer immunotherapy.

The colorectal adenocarcinoma segment of the colorectal cancer therapeutics industry is expected to reach USD 9.1 billion by end of 2032, due to its common occurrence.

North America market size was USD 5.3 billion in 2023 and is projected to grow at 4.5% CAGR through 2032, attributed to its rising cancer prevalence, and availability of advanced healthcare infrastructure.

Bristol-Myers Squibb Company, Celleron Therapeutics, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc, Novartis AG, Pfizer Inc, and Sanofi S.A. among others.